Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of atezolizumab/bevacizumab combination therapy in BCLC-C cirrhotic patients with hepatocellular carcinoma (HCC) according to the type of disease progression.
Authors
Spyridon Pantzios
Academic Department of Internal Medicine-Hepatogastroenterology Unit, General Oncology Hospital of Kifisia “Agioi Anargyroi”, National and Kapodistrian University of Athens, Athens, Greece;
Spyridon Pantzios , Antonia Syriha , Dionysia Mandilara , Ioanna Stathopoulou , Georgia Barla , Petros Galanis , Ioannis Elelfsiniotis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 557)
DOI
10.1200/JCO.2023.41.4_suppl.557
Abstract #
557
Poster Bd #
D9
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.
First Author: Robin Kate Kelley
Poster
2023 ASCO Annual Meeting
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
First Author: Kazuomi Ueshima
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Cabozantinib (CABO) tolerance and efficacy for patients with advanced hepatocellular carcinoma (HCC) after failure of sorafenib (SOR) in a French population: CLERANCE, a phase 4 trial.
First Author: Philippe Merle
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Multisite institutional study of efficacy and safety of cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma.
First Author: Mathias Earl Palmer